Skip to main content
. 2019 Feb 12;10(13):1272–1283. doi: 10.18632/oncotarget.26654

Figure 2. 3E10 scFv induces persistent DNA damage which confers synergism with an ATR inhibitor.

Figure 2

a. U251, U251+PTEN or astrocyte cells were treated with purified 2XMBP-scFv proteins for three days. The percent of cells with micronuclei was plotted for each treatment condition for each cell line. Each data point symbol represents the mean for each experimental replicate. Error bars represent the SEM; **P < 0.01 by unpaired t-test. b. Clonogenic survival assay results to determine the optimal dose range of the ATR inhibitor. Cells were seeded at low density into the ATR inhibitor. After 24 hours, the drug was removed and cells were allowed to grow in fresh media in order to assess colony formation. Error bars represent the SEM. c.-e. Clonogenic survival assays to interrogate synergism between 3E10 scFv and an ATR inhibitor. U251 cells (c), U251+PTEN cells (d) or astrocytes (e) were pretreated with the purified scFvs for 24 hours before reseeding at low density into the ATR inhibitor. After 24 hours, the drug was removed and cells were allowed to grow in fresh media in order to assess colony formation. Error bars represent the SEM; ****P < 0.0001, **P < 0.01, and *P < 0.05 by unpaired t-test. Synergism was assessed using the CompuSyn software.